INTRODUCTION
Increasing evidence emphasizes the need to ensure that vaccine antigens must be aptly presented to the immune system for maximal vaccine efficacy and that directly targeting the antigens to dendritic cells (DCs) represents an extremely promising strategy in this regard [1] [2] [3] . DCs represent a minimal proportion of the leukocytes in the blood and tissues, underscoring the necessity to design methods to efficiently target these rare cells for maximal immune activation. Circulating DCs exist in what is termed an immature state and must be activated into mature DCs to ensure appropriate immune activation for effective protection against a pathogen [4] . DC activation occurs as a result of triggering via tumor necrosis factor (TNF)-TNF receptor (TNFR) and Toll-like receptor (TLR) family members [2] . Maturation of DCs encompasses the up-regulation of costimulatory and adhesion molecule expression and increased secretion of interleukin (IL)-12 and IL-15, together favoring activation of potent T and B cell responses.
Two major populations of DCs exist, the CD11c ϩ CD123
-/low myeloid-derived DCs (MDCs) and CD11c -CD123 high plasmacytoid-derived DCs [PDCs; DCs typically lack markers of natural killer (NK) cell, T cell, B cell, and monocyte lineages (Lin -)]. MDCs and PDCs respond to stimuli (CD40L, bacteria, viruses; refs. [5] [6] [7] [8] [9] ) by up-regulating the expression of CD80 and CD86 coincident with their elevated immunostimulatory function. PDCs respond to influenza and herpes simplex viruses [5] [6] [7] or immunostimulatory oligodeoxynucleotides (ISSODNs) [10 -12] by secreting enormous amounts of type I interferons (IFNs), notably IFN-␣, which can drive the differentiation and activation of MDCs [13, 14] and PDCs [15] biasing toward strong T helper cell type 1 responses [16, 17] . Recent evidence revealed that MDCs also produce type I IFNs in response to viral infection [18] . Immunodeficiency viruses, human immunodeficiency virus [19, 20] , and simian immunodeficiency virus (SIV; N. Teleshova et al., submitted) also induce MDC/PDC-enriched populations to secrete IFN-␣. High levels of DC-produced type I IFNs likely play an important role in innate immunity and also provide a link to augment the adaptive immune system [14, [21] [22] [23] [24] .
Human studies suggest that DC numbers and function decrease with HIV disease progression [19, 25, 26] , underscoring the need to boost their functionality for future immune therapies. The rhesus macaque system is being used to study the targeting of circulating DCs in vaccine strategies against HIV infection [3] . Recent progress identified typical MDCs and PDCs residing in macaque blood and tissues of naïve [27, 28] , SIV ⌬nef-infected, and wild-type-challenged or SHIV162P-infected macaques (N. Teleshova et al., submitted). Typically representing less than 1% of total leukocyte suspensions [27, 28] , macaque DCs respond comparably with TLR and TNF-TNFR triggering, much like their human counterparts. Previous murine [29 -31] and human studies [32] [33] [34] demonstrated that subcutaneous (s.c.) administration of Flt3L significantly increased DC numbers in blood, lymphoid, and nonlymphoid tissues. In particular, the numbers of circulating CD11c ϩ
CD123
-/low MDCs and CD11c -CD123 high PDCs [32] [33] [34] increased ten-to 50-fold. Coates et al. [28] recently verified that a 10-day treatment with 100 g human Flt3L per kg per day readily mobilized functional macaque DCs, increasing the numbers of Lin -human leukocyte antigen (HLA)-DR ϩ DCs from 0.82% to 10.4% (ϳ13-fold increase) of the total blood leukocytes [28] .
Herein, we sort to characterize Flt3L-mobilized macaque DCs and delineate the optimal time of Flt3L treatment as well as the peak of DC mobilization under such conditions. We show that as little as 5-7 days of treatment of healthy adult macaques with Flt3L increases DC numbers as well if not better than the traditional 10-to 14-day treatment. Moreover, percentages among peripheral blood mononuclear cells (PBMCs) as well as the actual numbers of Lin -HLA-DR ϩ cells per ml blood continued to rise after the cessation of treatment, and the peak increases were detected ϳ4 days after such short-term treatment. Increased numbers of CD11c -CD123 -antigen-presenting cells (APCs) were also documented. Flt3L administration did not overtly activate the MDCs or PDCs, but both subsets up-regulated CD80 and CD86 expression upon culture, and the presence of CD40L enhanced this. This correlated with augmented IL-12 release by these cells. Flt3L-mobilized APCs were resilient to freezing and even exhibited enhanced viability upon in vitro culture. These data provide the first evidence for an effective, short-term Flt3L strategy that readily increases the numbers of healthy, functional DCs in macaque blood and will likely advance DC-targeted vaccine strategies against HIV as well as other pathogens.
MATERIALS AND METHODS

Reagents
Human Flt3L (Chinese hamster ovary) and human CD40L trimer were kindly provided by Amgen (Thousand Oaks, CA). The reagents were stored at -80°C until used at the indicated doses. Thawed aliquots of CD40L were kept at 4°C for up to 12 weeks.
Animals and treatment
Adult male and female Indian rhesus macaques (Macaca mulatta) were colonybred and housed at the Tulane National Primate Research Center (TNPRC; Covington, LA). At the commencement of these studies, all animals tested negative by polymerase chain reaction for simian type D retroviruses, simian T cell leukemia virus, and SIV. As some of the animals came from a previous study in which they were exposed to SHIV162P via the intravaginal route but had not reportedly become infected, we double-checked the plasma viral RNA levels in these animals during the study. Animals AM40, M010, P311, N833, AP37, and T693 were confirmed negative by bacterial DNA analyses (Ͻ250 copies/ml; Bayer Diagnostics, Emeryville, CA). However, AP85 showed up as a possible low-level infected animal with 298 viral copies per ml plasma (ϳ2.5 years after infection 
Cell isolation and culture
PBMCs were isolated from heparinized blood of treated and untreated macaques using Ficoll-Hypaque density gradient centrifugation (Amersham Pharmacia Biotec AB, Uppsala, Sweden). LN cell (LNC) suspensions were prepared using collagenase D digestion and mechanical disruption as described previously [35, 36] . Total single-cell suspensions were further enriched for DCs by depleting Lin ϩ cells expressing CD3, CD8, CD11b, CD14, and CD20. This was achieved using the Miltenyi AutoMACS System (Miltenyi Biotec, Auburn, CA), where cells were first labeled with fluorescein isothiocyanate (FITC)-conjugated antibodies (Ab) against CD3 (clone SP34); CD8 (clone SK1) and CD20 (clone L27), followed by incubation with anti-FITC, -CD11b (antimouse/human), -CD14 (anti-human), and -CD19 (anti-human) beads (Miltenyi Biotec); and collection of the flow-through Lin fraction (N. Teleshova et al., submitted). Whole-cell suspensions or Lin -DC-enriched cell mixtures were then analyzed by flow cytometry before and after in vitro culture.
The medium used for these studies was RPMI 1640 (Cellgro; Fisher Scientific, Springfield, NJ) containing 2 mM L-glutamine (Gibco-BRL Life Technologies, Grand Island, NY), 10 mM HEPES (Gibco-BRL Life Technologies), 50 M 2-mercaptoethanol (Sigma Chemical Co., St. Louis, MO), penicillin (100 U/ml)-streptomycin (100 g/ml; Gibco-BRL Life Technologies), and 1% heparinized human plasma. Cells were cultured at 1-2 ϫ 
Fluorescein-activated cell sorter (FACS) analysis
Ab used in this study are listed in Table 1 . MDCs and PDCs were identified and characterized using three-or four-color flow cytometry. FITC-anti-Lin Ab (CD3, CD8, CD11b, CD14, CD20) were used with APC-anti-HLA-DR and PE-anti-CD123. Anti-CD56 is excluded here and replaced by anti-CD11b and ϩ DCs have been excluded from these analyses. FITC-anti-Lin Ab, APC-anti-HLA-DR, Cyanti-CD80 or -CD86, and PE-anti-CD123 combinations were used to monitor CD80 and CD86 expression by the various subsets. To better define MDC and PDC subsets, FITC-anti-Lin Ab, PerCP-Cy5.5-anti-HLA-DR, PE-anti-CD123, and APC-anti-CD11c Ab were used (Table 1) . DCs were defined within the Lin -HLA-DR ϩ gate (first gated on total leukocytes to exclude neutrophils), and then a gate identifying CD123 ϩ , CD123 -CD11c ϩ , or CD123 -
CD11c
-cells was applied to define DC percentages (see Fig. 2A ). Isotypematched Ig controls were included for all experiments, and the mean fluorescence intensities (MFIs) of control Igs were routinely Ͻ1 log.
ELISA
Cell-free supernatants collected from the variously cultured cells were analyzed for the presence of IL-12 p70 as well as free p40 subunit (BioSource International Inc., Camarillo, CA).
Statistical analysis
The nonparametric-matched Wilcoxon test, the simple-sign test, and the parametric-paired difference t-test were performed to evaluate CD80 and CD86 expression on Lin -HLA-DR ϩ cells before and after Flt3L treatment.
RESULTS
Optimum DC yields after Flt3L treatment
Initial studies were performed to verify that human soluble Flt3L would function in rhesus macaques to mobilize DCs as seen in humans [32] [33] [34] , mice [29 -31] , and most recently, in monkeys [28] . Two healthy macaques received the standard s.c. dose of 100 g/kg/day Flt3L for 14 days. Blood and LN samples were taken before and 1 day after the completion of treatment, and additional blood samples were taken during treatment. Circulating DCs were identified within Lin -HLA-DR ϩ cells. In all samples, APC subsets were defined as CD123 ϩ PDCs and CD123 -cells (comprising MDCs and other APCs) [27, 28] . Typically, FITC-anti-Lin Ab were used with APC-anti-HLA-DR and PE-anti-CD123 Ab. In some experiments, FITC-anti-Lin Ab were combined with Cy5.5-anti-HLA-DR, PE-anti-CD123, and APC-anti-CD11c Ab to identify CD123 
Identifying the optimal treatment time for Flt3L mobilization
Knowing that the traditional 14-day Flt3L strategy mobilizes macaque DCs, we investigated whether shorter periods of treatment would equally mobilize DCs. This would be important to save precious reagents as well as to lessen the treatments that the animals endured. In addition, we were interested in determining how long the DC numbers remained elevated after the completion of Flt3L treatment. In total, we treated four animals for 5 days and seven animals for 7 days with daily 100 g/kg/day Flt3L s.c. administrations. All animals were monitored as frequently as possible during and after the treatment to assess more accurately the kinetics of DC mobilization.
The gating strategies used to define the subsets are shown in Figure 2A . The percentages of Lin -HLA-DR ϩ cells identified by flow cytometry at each time-point are displayed in Figure 2 , B and C. After 5 days of treatment, there was little increase in the Lin -HLA-DR ϩ cell frequency immediately after cessation of treatment, as evidenced by the low percentages shown 2 days after the end of treatment. However, Lin -HLA-DR ϩ cell percentages increased with time up to 13-25% (average of ϳ12-fold increase) 4 -6 days after the completion of the 5-day treatment (Fig. 2B, left) . Similar and even more striking results were obtained after only 7 days of Flt3L treatment, where greater increases were typically observed over time (Fig. 2B , Table 2 for this and a second Flt3L-treated animal. Isotype Ig controls were included in each experiment and showed MFIs of Ͻ1 log, with no detectable changes post-Flt3L treatment. (Fig. 2B , right, and Fig. 2C, left) . Lin -HLA-DR ϩ cell percentages tended to begin to decrease within 5-6 days and had returned to baseline levels within 2-3 weeks post-treatment.
More detailed analysis of the cells by flow cytometry confirmed that the CD123
ϩ PDCs represented only a small fraction of the Lin -HLA-DR ϩ cells, with ϳ93% of the Lin -HLA-DR ϩ cells being CD123 - (Fig. 2, A and C) . These ratios were similar after Flt3L treatment; however, there was an overall increase in the percentages of CD123 -cells (ϳ99% (Fig. 2C, right) . Thus, short-term Flt3L treatment predominantly mobilized CD123 -cells.
Mobilized DCs are immature, resilient to freezing, and can be enriched by lineage depletion
To characterize the Flt3L-mobilized DCs more carefully, the Lin -HLA-DR ϩ cells were stained with anti-CD80 or -CD86 in combination with anti-CD123 to delineate the levels of costimulatory molecules on the respective subsets (e.g., Fig. 2A) . Circulating CD123 -MDC-containing fraction and CD123 ϩ PDCs express low levels of CD80 and CD86 (Fig. 3) . Even after Flt3L mobilization, these cells maintained low-level expression of these molecules (Fig. 3) . However, upon analysis of the MFIs of multiple samples, it was clear that the APCs in the blood of Flt3L-treated animals exhibited slightly elevated CD80/CD86 levels. These levels were still representative of immature DCs (MFIs Ͻ100) but may reflect partial activation as a result of Flt3L treatment. The differences in CD80 and CD86 expression before and after Flt3L treatment did not reach statistical significance. We also tested the sensitivity of these cells to freezing and thawing to evaluate whether it was feasible to immediately store cells for later analysis. PBMCs collected 4 days after 7 days of Flt3L treatment (three separate animals) were processed immediately for FACS analysis, and the remainder of the cells was frozen (up to 20ϫ10 6 cells/ml in 1.8 ml cryo- tubes). After 6 -12 months in liquid nitrogen, the cells were thawed and analyzed by FACS. A representative FACS profile is shown in Figure 4A , where data on freshly isolated PBMCs versus frozen PBMCs from the same animal are provided. The significant Lin -HLA-DR ϩ subset is highlighted in each population. Examination of the percentages of these subsets in each sample revealed that freezing had little impact overall on Lin -HLA-DR ϩ cell percentages (Fig. 4B) . One animal exhibited a slight decrease, but the other two basically showed no changes in Lin -HLA-DR ϩ cell frequency after freezing. This observation was also repeated on two separate occasions with replicate samples of cells from AK66 collected 1 day postFlt3L treatment (not shown).
Although there is a significant increase in Lin -HLA-DR ϩ cells following Flt3L treatment, we wanted to determine if we could enrich the DCs to more closely monitor the functional capacities of these cells (below). To achieve this, PBMCs were depleted of Lin ϩ cells using the Miltenyi autoMACS System (Miltenyi Biotech, Auburn, CA), leaving the Lin -DC-enriched fraction behind. PBMCs were routinely depleted of
ϩ cells using combinations of directly labeled beads or FITC-labeled Ab followed by anti-FITC beads, as indicated in Materials and Methods. A representative FACS profile is shown (Fig. 5A) Figs. 2C and 5B), and there appeared to be no significant enrichment or loss of either subset.
DCs from Flt3L-treated macaques exhibit normal responsiveness to DC stimuli
Macaque DCs respond to classical TNF-TNFR and TLR stimuli [28, [37] [38] [39] . Using this knowledge, we cultured PBMCs or DC-enriched Lin -cells in the presence and absence of human CD40L trimer and monitored activity at the level of membrane phenotype and IL-12 release. CD80 and CD86 levels expressed by Lin -HLA-DR ϩ APCs in PBMCs or in Lin -cells dramatically increased after overnight culture in medium, and overall, the inclusion of CD40L had little additional influence on this (Fig. 6) . Note that the CD40L-induced up-regulation of CD80/CD86 was significantly more uniform in the Lin -cells compared with the medium-cultured cells or PBMCs (Fig. 6A) . Although the average MFIs were slightly lower, even Lin -HLA-DR ϩ APCs within previously frozen PBMCs readily up-regulated these molecules during culture (Fig. 6B) . Similar elevation of CD80/CD86 was observed on cultured Lin -cells (Fig. 6,  A and B) . It is interesting that further analysis of frozen samples revealed that Lin -HLA-DR ϩ APC percentages actually increased slightly after culture relative to the total leukocyte population (Fig. 6C) . An additional measure of DC/APC activation was performed by monitoring the release of IL-12 by activated DCs. Previous studies in humans [10, 40] and macaques [28] have shown that CD40L activation of MDCs and PDCs induces IL-12 production. Here, we tested whether Lin -HLA-DR ϩ APCs in blood collected 4 days post a 7-day Flt3L treatment would release IL-12 in response to stimulation. Some IL-12 is detected when PBMCs from untreated animals were cultured with CD40L, contrasting the significant levels released by PBMCs from Flt3L-treated animals in response to CD40L (Fig. 7, left) . CD40L-induced IL-12 levels ranged from 0 to 211 pg/ml secreted by cells from untreated animals up to 130 -550 pg/ml from the cells of Flt3L-treated monkeys. As predicted, even higher levels of IL-12 were secreted by DC-enriched Lin -cells after overnight culture in medium (35-990 pg/ml), and this was augmented in the presence of CD40L (93-1276 pg/ml; Fig. 7 , right).
DISCUSSION
HIV vaccines are fittingly tested in the SIV-rhesus macaque model to evaluate the capacity of immune responses to prevent new or control, established infections with immunodeficiency viruses [41] . Previous studies in the macaque using MoDCs or skin-derived DCs confirmed the similarities between human and macaque DC systems in basic biology as well as in how they interact with immunodeficiency viruses [37, 38, [42] [43] [44] [45] [46] [47] . Circulating blood DCs have been identified in macaques [27, 28] , and these cells respond to classical DC stimuli akin to human DCs [28] , further supporting the use of the macaque system to explore DCtargeted HIV vaccines as well as to ascertain the role of distinct DC subsets in HIV transmission and disease progression. In agreement with an earlier report [28] , we shown herein that ϳ7% of the Lin -HLA-DR ϩ cells were CD123 ϩ PDCs, and ϳ93% were CD123 -cells, which comprised ϳ57% CD11c ϩ MDCs as expected [28, 32, 33, 48] . DCs are a vital component of the immune system, and antigen must be processed and presented by properly activated DCs to guarantee that strong, active immunity against the foreign antigen is induced [2, 4] . Under this premise, progressively more strategies are being explored to encourage direct targeting of DCs in vivo with vaccine antigens to improve vaccine efficacy. As a result of the rarity of DCs circulating in the periphery, it is necessary to specifically home in on DCs via approaches targeting DC-restricted surface molecules [49] or increase the numbers of circulating DCs to render them more easily accessed by the incoming vaccine antigens. The latter is being investigated in a -cells prepared from blood drawn 4 days after a 7-day Flt3L treatment were cultured in the presence and absence of 1 g/ml CD40L for 24 h. After culture, the cell-free supernatants were collected and stored at -20°C before being analyzed by ELISA. Mean (ϮSEM) IL-12 levels (pg/ml) produced are graphed for each cell preparation from four different donor animals. number of ways using recombinant factors that mobilize cells from the bone marrow to elevate the DC numbers circulating in the periphery [29, 33, 50, 51] . Earlier, more extensive studies, first in mice [29 -31] and then in humans [32] [33] [34] , demonstrated how s.c. Flt3L administration mobilized DCs readily, increasing their numbers up to 50-fold above the basal levels. Flt3L increased MDC and PDC subsets [32] [33] [34] , and MDC numbers are augmented more dramatically than PDCs. Here, and in the recent report from Coates et al. [28] , mobilization of functional DCs has been confirmed to occur comparably in the macaque in response to human Flt3L. What is more, we now show that a considerably shorter treatment time is sufficient to similarly mobilize DCs and that the peak in DC percentages occurs within a few days of completing the treatment, not immediately afterwards, which is when researchers typically monitored DC numbers after longer times of Flt3L dosing [33, 51] . Analogous data can be achieved using a human Flt3L-IgG 2 fusion protein to mobilize DCs in rhesus macaques and sooty mangabeys (Mark Feinberg, personal communication DCs mobilized by this short-term treatment are functional, responding to a classical DC stimulus, CD40L, by secreting IL-12 and increasing the expression of costimulatory CD80 and CD86 molecules. This is especially encouraging for the use of smaller amounts of the mobilizing agent (in this case, Flt3L) and reflects a regimen that is clearly more acceptable for an individual to tolerate. In fact, a single dose of Flt3L administered intratracheally to rats was recently shown to increase DCs and T cells in the local tissues, peaking 3 days later and resulted in enhanced Ab responses following immunization with tetanus toxoid [52] . The fact that less agent is needed to effect significant DC mobilization is also heartening for the potential application of DNA vaccines in which the Flt3L gene is incorporated, where less protein would be expected to be expressed but might be sufficient for DC mobilization. Early reports favor the possibility that DNAs encoding Flt3L can mobilize DCs and enhance responses against peptide [53] or DNA [54] vaccines.
Although it has been reported that additional stimulation of Flt3L-mobilized DCs was necessary to activate the immune system appropriately [55, 56] , it seems that under some conditions, Flt3L-mobilized DCs can enhance the immune responses against an antigen even in the absence of additional activation [53, 54] . The route of Flt3L administration, the route of immunization, and/or the type of antigen may influence this. Our studies reveal that although Flt3L-mobilized DCs appear immature, they may have slightly elevated CD80/CD86 levels (compared with the levels detected before treatment), indicative of some activation. These costimulatory molecules are uniformly up-regulated at least tenfold, especially in enriched Lin -cell cultures exposed to CD40L (likely as a result of increased DC-DC communication), underscoring their responsiveness to stimuli. In separate studies, more extensively characterizing MDC and PDC function in uninfected versus SIV ⌬nef-infected and wild-type-challenged or in SHIV162P-infected macaques that have not received Flt3L, similar DC activation occurs in response to culture with CD40L (N. Teleshova et al., submitted). However, in the absence of Flt3L treatment, the elevation of CD80/CD86 expression is less dramatic in response to medium culture and requires triggering via CD40L or ISS-ODNs to be impacted significantly. Of note, the peak MFIs after CD40L or ISS-ODN stimulation reach ϳ300 as opposed to the MFIs of ϳ1000 seen in Flt3L-mobilized DCs after culture in medium or CD40L. This further suggests that Flt3L treatment has heightened the sensitivity of DCs to activation, explaining how additional exogenous activation may be less critical for optimal presentation upon antigen exposure. Moreover, the Flt3L-mobilized DCs possess heightened viability as demonstrated by the increases in DC numbers relative to other leukocytes after overnight culture. This contrasts what we have observed in cells from non-Flt3L-treated animals (N. Teleshova et al., submitted) and suggests Flt3L boosts DC viability.
Therefore, there is increasing evidence that human Flt3L can augment DC and possibly other APC numbers in nonhuman primates. Furthermore, we have identified that shortterm treatment is sufficient to mobilize DCs and that the peak of the increase in DC frequency occurs within a few days of completing treatment. Such strategies will likely advance the targeting of DCs with putative HIV vaccines in vivo as well as allowing more detailed analysis of the role of DCs in HIV transmission.
